Trevi Therapeutics Inc
Research Trevi Therapeutics Inc (TRVI) on Bullrun: market cap USD 2.56B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTRVI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.56B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 17.80M
- Free cash flow-USD 17.55M
Valuation Snapshot
latest market cap is USD 2.56B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 42.76M | -USD 42.10M | n/a | -0.32 | USD 18.91M | USD 753.00K | USD 183.24M |
| FY2024 | USD 0 | -USD 47.91M | -USD 38.29M | n/a | -0.47 | USD 34.10M | USD 1.03M | USD 99.64M |
| FY2023 | n/a | -USD 29.07M | -USD 31.85M | n/a | -0.29 | USD 32.40M | USD 1.34M | USD 82.55M |
| FY2022 | n/a | -USD 29.15M | -USD 28.33M | n/a | -0.45 | USD 12.59M | USD 12.52M | USD 107.46M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.56B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.61B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 385.64M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 85.57M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 115.65M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 22.23M | n/a | n/a | n/a |
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Trevi Therapeutics Inc's market cap?
Trevi Therapeutics Inc's market capitalization is USD 2.56B.
What does Trevi Therapeutics Inc do?
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc.